[ad_1]
At a press conference on Wednesday, Ursula von der Leyen affirms that the first vaccines will not be ready until April 2021.
He also said they hope to be able to deliver up to 50 million vaccines to the EU a month, Reuters reports.
In the past, there have been optimistic forecasts from pharmaceutical companies. Ministerial Counselor Bjørn-Inge Larsen said earlier this year that they received feedback that they can administer vaccines during 2020.
– Based on that, it’s not entirely unreasonable that we vaccinated two-thirds of the adult population during 2021, Larsen said.
Will emphasize uncertainty
At a press conference on the status of the crown on Wednesday, TV 2 asked Camilla Stoltenberg, director of FHI, what she thought about the EU Commission’s estimates.
– What do we know about when the vaccine can reach the Norwegian market?
– We have been concerned to emphasize the uncertainty of when a vaccine may arrive. That estimate is perhaps the best we have at the moment, Stoltenberg says.
At the same time, it emphasizes that the situation will continue to change.
– The time can be shortened as the situation is so demanding in many parts of the world or it may take longer due to something that happens during the trial, he says.
FHI says that when the vaccine goes on the market depends on several factors.
– Therefore, you must be careful to say when it comes. We work as quickly as possible and it gives hope. There is hope that it will arrive faster than a similar vaccine has ever done in world history, Stoltenberg says.
– Vaccine ready in November
The Pfizer company writes that they may have a vaccine ready during the third week of November.
– Let me be clear, as long as we get positive results, then Pfizer will apply for the use of emergency authorization in the US Just after the safety milestone is reached in the third week of November, the company director writes, Albert Bourla, in an open letter.
An emergency approval will mean that healthcare professionals treating corona patients, as well as people at risk, can receive the vaccine before US authorities have approved it for public use.
Agreement with the EU
In October, Pfizer submitted its top candidate for a coronary vaccine to the European Medicines Agency EMA.
Pfizer will now submit the test results data to the EMA. In this way, the EMA will be able to assess whether the vaccine should be approved for use in Europe.
The company writes that they want to know if the vaccine is effective against the coronavirus by the end of October.
German Biontech is collaborating with American Pfizer to develop the vaccine, which may be available for EU countries, as well as Norway, when it is fully developed.
